

Tamm-Horsfall protein in recurrent calcium kidney stone formers with positive family history: abnormalities in urinary excretion, molecular structure and function

Markus Jaggi · Yasushi Nakagawa · Ljerka Zipperle · Bernhard Hess

Received: 14 November 2006 / Accepted: 10 February 2007 / Published online: 8 March 2007
© Springer-Verlag 2007

Abstract Tamm-Horsfall protein (THP) powerfully inhibits calcium oxalate crystal aggregation, but structurally abnormal THPs from recurrent calcium stone formers may promote crystal aggregation. Therefore, increased urinary excretion of abnormal THP might be of relevance in nephrolithiasis. We studied 44 recurrent idiopathic calcium stone formers with a positive family history of stone disease (RCSF_{fam}) and 34 age- and sex-matched healthy controls (C). Twenty-four-hour urinary THP excretion was measured by enzyme linked immunosorbent assay. Structural properties of individually purified THPs were obtained from analysis of elution patterns from a Sepharose 4B column. Sialic acid (SA) contents of native whole 24-h urines, crude salt precipitates of native urines and individually purified THPs were measured. THP function was studied by measuring inhibition of CaOx crystal aggregation in vitro (pH 5.7, 200 mM sodium chloride). Twenty-four-hour urine excretion of THP was higher in RCSF_{fam} (44.0 ± 4.0 mg/day) than in C (30.9 ± 2.2 mg/day,

$P = 0.015$). Upon salt precipitation and lyophilization, elution from a Sepharose 4B column revealed one major peak (peak A, cross-reacting with polyclonal anti-THP antibody) and a second minor peak (peak B, not cross-reacting). THPs from RCSF_{fam} eluted later than those from C ($P = 0.021$), and maximum width of THP peaks was higher in RCSF_{fam} than in C ($P = 0.024$). SA content was higher in specimens from RCSF_{fam} than from C, in native 24-h urines (207.5 ± 20.4 mg vs. 135.2 ± 16.1 mg, $P = 0.013$) as well as in crude salt precipitates of 24-h urines (10.4 ± 0.5 mg vs. 7.4 ± 0.9 mg, $P = 0.002$) and in purified THPs (75.3 ± 9.3 µg/mg vs. 48.8 ± 9.8 µg/mg THP, $P = 0.043$). Finally, inhibition of calcium oxalate monohydrate crystal aggregation by 40 mg/L of THP was lower in RCSF_{fam} ($6.1 \pm 5.5\%$, range -62.0 to $+84.2\%$) than in C ($24.9 \pm 6.0\%$, range -39.8 to $+82.7\%$), $P = 0.022$, and only 25 out of 44 (57%) THPs from RCSF_{fam} were inhibitory (positive inhibition value) vs. 25 out of 34 (74%) THPs from C, $P < 0.05$. In conclusion, severely recurrent calcium stone formers with a positive family history excrete more THP than healthy controls, and their THP molecules elute later from an analytical column and contain more SA. Such increasingly aggregated THP molecules predispose to exaggerated calcium oxalate crystal aggregation, an important prerequisite for urinary stone formation.

M. Jaggi · L. Zipperle · B. Hess
Renal Stone Clinic and Stone Research Laboratory,
Policlinic of Internal Medicine, University Hospital,
Berne, Switzerland

Y. Nakagawa
Kidney Stone Laboratory,
University of Chicago, Chicago, IL, USA

M. Jaggi
Department of Anesthesiology,
Kantonsspital, 6000 Lucerne, Switzerland

B. Hess (✉)
Internal Medicine and Nephrology, Klinik Im Park,
Bellariastrasse 38, 8038 Zurich, Switzerland
e-mail: bernhard.hess@hirslanden.ch

Keywords Nephrolithiasis · Positive family history · Calcium oxalate · Tamm-Horsfall protein · Sialic acid · Crystal aggregation inhibition

Introduction

Tamm-Horsfall protein (THP) is the most abundant urinary protein in healthy humans [1, 2]. Over the years, THP has

been described as a regulator of intrarenal cytokines, a contributor to tubulointerstitial renal disease, a trigger of cast nephropathy in multiple myeloma and a natural defense against bacterial infection in the urinary tract [1]. Most recent studies have emphasized the role of THP as a general defense factor against uropathogenic microorganisms, especially type 1 fimbriated *Escherichia coli* [3, 4]. THP inhibits apoptosis and chemotaxis of isolated polymorphonuclear leukocytes, whereas phagocytosis is stimulated [5].

In addition, for many years, THP has been known for its involvement in urinary crystallization and stone formation. This has most recently been emphasized by the demonstration of a dramatic increase in spontaneous calcium oxalate crystal formation in THP knockout mice in comparison with wild-type mice, at least under conditions of excessive calcium and oxalate intake [6]. In human urine, crystal nucleation occurs opportunistically and quite abundantly [7], in normals and stone formers alike [8]. Whereas growth of nucleated microcrystals, at least for calcium oxalate, is too slow to produce particles of clinically relevant sizes, it is by means of crystal aggregation that larger particles form [7, 9]. Particle formation in the urinary tract occurs under exquisite control of macromolecular modulators of crystallization [10, 11], i.e., particles form as a result of intimate interactions between newly forming inorganic crystal surfaces and organic macromolecules [10, 11]. In animal models, the synthesis of THP as well as other urinary macromolecules by renal cells is increased upon exposure to high oxalate concentrations or calcium oxalate crystals [10]. By reversibly binding at newly forming crystal surfaces, THP strongly enhances electrostatic surface charge and viscous binding forces, whereby it affects the process of crystal aggregation [11, 12].

However, controversy exists as to whether THP is a promoter or an inhibitor of the aggregation of calcium oxalate crystals in human stone formers. In vitro, urine-like concentrations of THP powerfully inhibit crystal aggregation [11], but rising concentrations of calcium, sodium, hydrogen ions and of THP itself progressively decrease its inhibitory activity [12]. Under urine-like conditions of low pH and high sodium concentration, some structurally abnormal THPs from recurrent calcium stone formers even become promoters of crystal aggregation in vitro [13, 14]. The molecular basis of this abnormality, which may be inherited [15], may involve posttranslational changes in glycosylation, which determine the biologic activity of THP [1]. Indeed, reduced terminally linked sialic acid (SA) has been found in a few stone former THPs [16].

Because high concentrations of THP molecules promote crystal aggregation at high urinary concentrations of calcium and/or sodium, increased urinary THP excretion rates might be of pathophysiological relevance in nephrolithiasis. However, we have demonstrated that urinary THP excretion

was not different from normal subjects in non-selected recurrent kidney stone formers [17]. Since THP abnormalities may be inherited [15], the present study aimed at measuring THP excretion in highly selected recurrent idiopathic calcium renal stone formers with a positive family history of stone disease (RCSF_{fam}), in comparison with healthy controls. Furthermore, we wanted to evaluate structural and functional properties of individually purified THP molecules from RCSF_{fam} and healthy controls.

Subjects and methods

Study subjects

A total of 78 subjects, 44 recurrent calcium stone formers with a positive family history (RCSF_{fam}), and 34 age- and sex-matched controls (C), were studied. Except for one C and one RCSF_{fam}, no materials from subjects who had participated in our previous study on THP abnormalities in calcium oxalate nephrolithiasis [15] were used for the present experiments. Out of 254 consecutive stone formers originally referred to the Renal Stone Clinic at the University of Berne, Switzerland, for metabolic evaluation over a period of 3.25 years, we identified 35 (13.8%), 31 men and four women, with a positive family history for kidney stone disease (i.e., patients indicated a history of kidney stones in parents, grandparents, siblings, uncles or aunts) and meeting the following criteria: (1) recurrent calcium nephrolithiasis, i.e., passage from at least two calcium-containing stones, defined either by stone analysis (X-ray diffraction or infrared spectroscopy) or disappearance of opaque material on conventional radiographs; (2) idiopathic calcium stone disease, i.e., patients with or without idiopathic hypercalciuria, hyperoxaluria, hyperuricosuria or hypocitraturia; (3) normal renal function, i.e., plasma creatinine concentration less than 115 $\mu\text{mol/L}$. Nine additional patients (six men, three women) meeting identical criteria were recruited from the Kidney Stone Laboratory at the University of Chicago for additional work-up of individual THP molecules. Excluded were all patients who exhibited well-defined causes of hypercalciuria (primary hyperparathyroidism, hypercalcemia associated with malignancy or immobilization, excess intake of vitamin D, sarcoidosis, renal tubular acidosis and medullary sponge disease), hyperoxaluria (primary hyperoxaluria, malabsorption with steatorrhea due to inflammatory bowel disease or short bowel syndrome) or hypocitraturia (renal tubular acidosis, malabsorption with steatorrhea or chronic urinary tract infection). In total, 44 RCSF_{fam}, 37 men and seven women, were selected for studies. Their mean age was 43.4 ± 1.6 years (range 27–67), and they were severely recurrent stone formers, having formed a mean of 10.8 ± 2.0 stones (range 2–50). All

medications possibly interfering with urinary determinants of THP excretion, i.e., calcium, citrate and uric acid [17], were discontinued at least 2 weeks before urine collection.

In comparison, a total of 34 controls (C), 25 men and nine women, were studied. Twenty-six (21 men and five women) control subjects were recruited from the University of Berne, and eight (four men, four women) from the Kidney Stone Laboratory of the University of Chicago. Their mean age was 39.1 ± 1.7 years (range 23–69), not different from RCSF_{fam}. All control subjects were without a personal or family history of renal stone formation and not were taking any medication interfering with urinary determinants of THP excretion.

Experimental procedures

Table 1 summarizes all experimental procedures that are outlined in detail in the subsequent paragraphs. Except for 24-h excretion rates of THP, routine 24-h urine chemistries are not reported here, since the purpose of this study was to investigate individual THP molecules irrespective of 24-h urine compositions.

Measurements of urinary Tamm-Horsfall protein

For logistic reasons, 24-h excretion rates of urinary THP were measured in only one 24-h urine specimen of all subjects from the University of Berne (35 RCSF_{fam}, 26 C). It has to be acknowledged that the day-to-day variability for THP in human urine amounts to 11% [18]. As previously described [17], THP was measured by a commercially available indirect non-competitive enzyme-linked immunosorbent assay (Syn^{elisa} Tamm-Horsfall protein, Pharmacia & Upjohn/Elias Diagnostics, Freiburg, Germany), whereby monoclonal mouse anti-human THP antibodies, immobilized on pins, bind THP antigen from standards (0–3.5–8–20–50–120 mg/L in phosphate-buffered saline) and urine samples. The antigen–antibody complexes associate with an enzyme-labeled polyclonal sheep anti-human THP antibody, which subsequently converts added substrate to form a colored solution, monitored at 492 nm.

Using this method, normal urinary excretion rates of THP have been found to be 9.3–35.0 mg/day for men and 9.0–36.3 mg/day for women, respectively (5th–95th percentile). All freshly collected 24-h urines were carefully shaken for 2 min at room temperature in order to avoid losing large THP polymers for analysis due to settling. Immediately thereafter, 10 µL-aliquots were aspirated and diluted 1:100 with the denaturing sample buffer supplied with the ELISA kit. All incubations were carried out at room temperature, and measurements were performed in duplicate. Coefficients of variation were 5.0–5.2% for intra-assay variability and 7.8–9.2% for inter-assay variability.

Table 1 Summary of experimental procedures applied and materials used throughout the study. For details, see Sect. “Subjects and methods”

THP measurements (ELISA):

- Native 24-h urines (35 RCSF_{fam} and 26 C)

Chromatography (24-h urines of all 78 study subjects):

Whole urines + 0.58 M NaCl \Rightarrow centrifugation

\Rightarrow dialysis against H₂O (3 x) \Rightarrow lyophilization

+ 4 M Urea/0.02 Na-Phosphate \Rightarrow passage through Sepharose

4B column \Rightarrow lyophilization of major peak A (= THP) +

minor peak B

Cross-reaction with THP antibody:

-Peaks A and B (materials from 7 RCSF_{fam} and 7 C)

Sialic acid determination by acid hydrolysis:

-Native 24-h urines (35 RCSF_{fam} and 26 C)

-Crude salt precipitates of 24-h urines (35 RCSF_{fam} and 26 C)

-ALL 78 peak A lyophilizates (= THP)

-17 peak B lyophilizates (9 RCSF and 8 C)

Crystal aggregation inhibition in vitro:

-40 mg/l of all 78 lyophilized THPs (peak A) at pH 5.7, 200 mM NaCl

Purification/elution pattern of THPs

General procedure

From individual whole 24-h urines, THP was precipitated by adding 0.58 M NaCl according to Fletcher et al. [19]. Salt precipitates were dialyzed three times for 24 h against distilled water at 4°C and then lyophilized. This purified material was subsequently dissolved in a solution containing 4 M urea and 0.02 M sodium phosphate, pH 6.8, whereby urea was recrystallized from 70% ethanol before use. Thereafter, the material was passed through a Sepharose 4B column (Sepharose 4B, 2 cm \times 100 cm, Pharmacia, Switzerland), as previously described [13]. Eluates were collected by an automated fraction collector (1.5 mL/tube), and absorbance of fractions was measured at 277 nm [14].

As demonstrated in Fig. 1 for two representative individuals (one C, one RCSF_{fam}), materials usually eluted as one major peak (peak A) and a second minor peak (peak B). Since only peak A material had originally cross-reacted in an ELISA with a polyclonal anti-THP antibody raised in rabbits (Biomedical Technologies, Stoughton, MA, USA), all elution fractions from peaks A were pooled, subsequently lyophilized and stored at 4°C for further experiments. For all individual eluates of THPs, maximum absorbance (i.e., maximum height of peaks), fraction numbers at maximum absorbance (i.e., peak position) and numbers of fractions from the beginning to the end of peaks (i.e., maximum width of peaks) on elution diagrams were




Fig. 1 Elution patterns of salted-out and dialyzed/lyophilized materials on a Sepharose 4B column (two representative individuals, one C and one RCSF_{fam}). For details, see text

registered. Maximum width of peaks A was taken as a rough estimate of the amount of eluted THP.

Sialic acid measurements

Sialic acid was measured using the thiobarbituric assay described by Aminoff [20]. Briefly, after oxidation with periodic acid (25 mM in 0.125 N H₂SO₄, pH 1.2) and reduction of excess periodate with sodium arsenite (2 vol% in 0.5 N HCl), 2-thiobarbituric acid (0.1 M aqueous solution, pH 9.0) is added and heated for 7.5 min in a boiling water bath. The colored solution is cooled on ice, followed by extraction with acid butanol (butan-1-ol, addition of 5 vol% 12 N HCl). The absorbance at 549 nm in the butanol layer is directly proportional to the SA concentration, with a molar extinction of 70.7×10^3 [20]. A calibration curve was constructed by using 5–40 μg of *N*-acetyl-neuraminic acid in aqueous solution.

The SA content was measured in four types of specimens (Table 1).

Native 24-h urines

A sample of 0.5 mL of native 24-h urine was directly used for the thiobarbituric assay, as described above. The amount of SA in whole 24-h urines was obtained from extrapolating the SA content in 0.5 mL whole urine to the respective 24-volume. This was performed in native urines of all subjects from the University of Berne.

Crude salt-precipitates of 24-h urines

To 20 mL of native 24-h urines, 0.58 M NaCl (0.68 g) was added. After stirring overnight and centrifugation at 5,000 rpm for 15 min, precipitates were separated from supernatants. Precipitates were then brought back to their original volume by adding distilled H₂O. In order to make

sure that precipitates were richer in THP than supernatants, as assumed, we measured THP concentrations both in supernatants and precipitates from 22 subjects (11 RCSF, 11 C) by ELISA (described above) in a preliminary study. THP concentrations amounted to 15.5 ± 2.3 mg/L in precipitates and 1.9 ± 0.3 mg/L in supernatants, respectively ($P = 0.0001$), thus proving that major amounts of THP were present in precipitates. Therefore, SA contents were subsequently determined in crude salt precipitates of all 24-h urines from subjects of the University of Berne.

Hydrolysis of precipitates was performed by adding 50 mM H₂SO₄ and incubating at 80°C for 60 min. Thereafter, pH was adjusted to 5.5. After dialysis against 30 mL of H₂O for 24 h, diffusates were lyophilized and then redissolved in 1 mL water. In 0.5 mL of this solution, SA content was measured according to Aminoff [20] as described above, and the amount of SA in the precipitate of the whole 24-h urine was calculated.

Purified THPs (peaks A eluting from Sepharose 4B column)

Two milligrams of all lyophilized THPs (major peak A, see above) were dissolved in 2 mL of 50 mM H₂SO₄ overnight. Undissolved material was removed by centrifugation at 3,000 rpm for 10 min. Thereafter, THP concentration in solution was measured by the extinction at 277 nm [13, 14]. Hydrolysis was then obtained by incubating 1 mL of this THP solution at 80°C for 60 min. After adjustment of the pH to 5.5, the sample was dialyzed for 24 h against 30 mL of H₂O, and the diffusate was lyophilized. The lyophilisates were redissolved in 1 mL of H₂O, and SA content was determined in 0.5 mL of this solution as described above. Subsequently, the SA content per milligram of lyophilized THP was calculated.

Second peaks (peaks B eluting from the Sepharose 4B column)

Of original salt precipitates from subjects recruited at the University of Chicago, material eluting as second peak (peak B) was additionally pooled and lyophilized, and the SA content per milligram of this material was also calculated.

Measurements of calcium oxalate crystal aggregation

The aggregation of calcium oxalate monohydrate (COM) crystals in vitro was measured as previously described in detail [13–15]. Briefly, COM crystals (0.7 mg/mL) in a solution containing 200 mM NaCl and 10 mM sodium acetate, pH 5.70, are stirred overnight at 37°C under constant stirring (850 rpm) in order to obtain a homogeneous slurry. After preincubation with small amounts (<5 vol%) of aque-

ous solutions of THPs in order to reach final assay concentrations of 40 mg/L, additional particle aggregation is induced with stirring at slower speed (500 rpm) for 180 s in a spectrophotometric cuvette [13–15]. Thereafter, spontaneous particle sedimentation is monitored at 620 nm, whereby the rate of decrease of absorbance at 620 nm over time, called turbidity slope T_S , reflects particle size [13–15]. The T_S values in control slurries (T_{SC}) are taken as 100% aggregation, and percent crystal aggregation in presence of THPs is calculated as $(T_S/T_{SC}) \times 100$. Percent inhibition of COM crystal aggregation is calculated as $100\% - \% \text{ aggregation}$, whereby a negative inhibitory activity indicates promotion of COM crystal aggregation [13–15].

Crystal aggregation experiments were performed in the presence of 40 mg/L lyophilized and dissolved THP (peak A material, see above) of all 78 study subjects.

Statistics

All values are presented as mean \pm SE. For comparisons between groups, non-parametric Mann–Whitney U -test was used, whereas Wilcoxon signed-rank test was applied for within-group comparisons, and observed frequencies were compared by χ^2 statistics. Simple and multiple linear regression analysis was performed for correlation studies.

Results

Measurements of urinary Tamm-Horsfall protein

As shown in Fig. 2, 24-h urine excretion rate of THP was higher in RCSF_{fam} (44.0 ± 4.0 mg/day) than in C (30.9 ± 2.2 mg/day, $P = 0.015$). When considering all 61 subjects in whom urinary THP had been measured (35 RCSF_{fam}, 26 C), THP excretion rate was positively correlated with the amount of SA detected in crude salt precipitates of whole 24-h urines (see below), $R = 0.565$, $P = 0.0001$. This correlation also persisted when calculated separately for RCSF_{fam} ($R = 0.691$, $P = 0.0001$) and C ($R = 0.490$, $P = 0.011$), respectively.

Purification/elution pattern of THPs

As depicted in Fig. 1 for two representative individuals, elution from the column was delayed in THPs (peaks A) from RCSF_{fam} (fraction number at maximum absorbance 53.5 ± 2.1) in comparison with THPs from C (46.1 ± 1.9 , $P = 0.021$). The maximum peak absorbance was not different between RCSF_{fam} (0.267 ± 0.067) and C (0.244 ± 0.020). However, maximum width of peaks A, i.e., number of fractions from the beginning to the end of the eluted peak A material—a rough measure of the amount

of eluted THP—was higher in RCSF_{fam} (45.1 ± 3.4) than in C (34.5 ± 2.0 , $P = 0.024$). The higher amounts of THP daily excreted in urine by RCSF_{fam}, as measured by ELISA (Fig. 2), were marginally and positively correlated with the widths of peak A ($R = 0.255$, $P = 0.049$).

For peak B materials, there was a trend for coming off the column later in RCSF_{fam} (fraction number at maximum absorbance 114.4 ± 3.6) than in C (fraction number 107.4 ± 3.8), and maximum absorbance of peaks B tended to be lower in RCSF_{fam} (0.137 ± 0.050) than in C (0.159 ± 0.064 , $P = 0.072$).

Sialic acid measurements

Figure 3 depicts the results of SA measurements. In native whole 24-h urines (Fig. 3 a), the total amount of SA excreted in urines from healthy controls was 135.2 ± 16.1 mg/24 h, lower than in RCSF_{fam} who excreted 207.5 ± 20.4 mg/24 h ($P = 0.013$). SA contents in crude salt precipitates of 24-h urines, presumably THP, were 7.4 ± 0.9 mg/24 h in controls and 10.4 ± 0.5 mg/24 h in RCSF_{fam} ($P = 0.002$, Fig. 3b, left). Measured in lyophilisates of peaks A (=THP), the SA content was 48.8 ± 9.8 μ g/mg THP in C, significantly lower than in RCSF_{fam} (75.3 ± 9.3 μ g/mg THP, $P = 0.043$, Fig. 3b, right). The amount of THP daily excreted in urine was positively related to the amount of SA detected in crude salt precipitates of urines (presumably THP), $R = 0.565$, $P = 0.0001$.

Sialic acid content of peak B material, measured in selected subjects recruited at the University of Chicago (seven C, seven RCSF_{fam}), again tended to be lower in C (47.6 ± 15.8 μ g/mg) than in RCSF_{fam} (63.0 ± 27.4 μ g/mg of protein, NS).

Measurements of calcium oxalate crystal aggregation

Values of inhibitory activity toward COM crystal aggregation by 40 mg/L of THP widely overlapped between pro-




Fig. 2 Daily urinary THP excretion rates in RCSF_{fam} and C




Fig. 3 Results of sialic acid measurements in whole native 24-h urines (a) as well as crude salt precipitates from whole urines and salt-precipitated and purified THPs (b). For details, see text

teins from C (range -39.8 to $+82.7\%$) and from RCSF_{fam} (range -62.0 to $+84.2\%$), but were significantly higher for THPs from C ($24.9 \pm 6.0\%$) than from RCSF_{fam} ($-6.1 \pm 5.5\%$, $P = 0.022$ vs. control THPs), as depicted in Fig. 4. Under the experimental conditions of the present study (pH 5.70, 200 mM NaCl), 25 out of 34 (73.5%) THPs from controls were inhibitory, compared with 25 out of 44 THPs (56.8%) from RCSF_{fam} ($\chi^2 = 4.84$, $P < 0.05$). Crystal aggregation measurements were not significantly related to any of the analytical measures, i.e., THP excretion rates, SA measurements or electrophoretic patterns, neither in RCSF_{fam} nor in C.

Discussion

This study demonstrates that every seventh patient with recurrent idiopathic calcium renal stone disease referred to our stone clinic had a positive family history, defined as history of kidney stones in parents, grandparents, siblings, uncles or aunts (RCSF_{fam}). The study represents the largest




Fig. 4 Inhibition of calcium oxalate monohydrate crystal aggregation in vitro by 40 mg/L of purified THP at pH 5.70 and 200 mM NaCl. For details, see text. Negative value for inhibition = promotion of crystal aggregation

investigation on urinary THP in a group of such highly selected RCSF_{fam}. Our main findings are that (1) RCSF_{fam} excrete significantly more THP than age-matched controls, (2) THPs from RCSF_{fam} and C are structurally different, as demonstrated by elution patterns from an analytical column and SA measurements and (3) THP molecules from RCSF_{fam} are weaker inhibitors of calcium oxalate crystal aggregation than normal THPs.

Several studies have looked at urinary excretion rates of THP in kidney stone formers and healthy controls. In studies using quantitative electroimmunodiffusion, THP excretion rates were 40–50 mg/day, without differences between stone formers and healthy subjects [21, 22]. More recent studies used radioimmunoassay or ELISA and demonstrated that THP excretion rates varied more widely among subjects, generally ranging between 10 and 70 mg/day [17, 23–26]. THP excretion rates were either equal to healthy controls [23, 24] or reduced in “common” stone formers [17, 25, 26]. The latter was at least partly due to the fact that some studies included uric acid stone formers in whom ELISA measurements have indicated lower THP excretions rates [17, 27]. The increased amounts of urinary THP measured in RCSF_{fam} in the present study may reflect a truly increased renal THP production. However, they might also result from an increased number of THP-binding sites exposed to the THP antibody, due to conformational changes in proteins from RCSF_{fam}.

Indeed, conformational alterations appear to be operational, as suggested by the delayed elution of lyophilized stone former THPs from a Sepharose column. A very similar pattern was found in a small number of stone formers in a previous study where delayed elution from a Sephacryl S-200 column in THPs from stone formers, but not from healthy controls, occurred [15]. Apparently, THP molecules after salting-out from whole urine occur in at least two different states of molecular aggregation, and urines of RCSF_{fam} contain relatively more aggregated THP which predisposes to delayed elution from an analytical column. These findings are in keeping with our previous work demonstrating increased viscosities and higher apparent molecular masses of stone former THP isolated from whole urine under the same experimental conditions [14, 15].

The role of SA content of THP molecules with respect to urinary stone formation has been addressed previously. Knörle et al. [16] compared individually purified THPs from ten healthy controls and ten recurrent calcium oxalate stone formers and found that stone formers' THPs contained significantly less SA. Similar findings were most recently obtained by Sumitra et al. [28], who compared 100 controls and 200 not-further-specified hyperoxaluric renal stone formers. Using the same thiobarbituric assay, we measured 49 ± 10 µg/mg THP in controls, identical to the 51 ± 9 µg/mg and the 50 ± 6 µg/mg THP obtained in healthy

controls by Knörle et al. [16] and Sumitra et al. [28], respectively. Differences between these studies and our investigation, however, exist in stone former THPs: SA content of THP in our highly selected RCSF_{fam} was $75 \pm 9 \mu\text{g}/\text{mg}$ THP, higher than the $21 \pm 4 \text{ g}/\text{kg}$ in the ten stone formers of Knörle et al. [16] and the $28 \pm 3 \mu\text{g}/\text{mg}$ in the 200 hyperoxaluric stone formers of Sumitra et al. [28]. We did not obtain data on SA contents of THPs from “ordinary” calcium stone formers without positive family history, but based on the identical SA contents of normal THPs in three different studies [16, 28, present work], the difference in SA content of stone former THPs between our study and the studies by Knörle et al. [16] and Sumitra et al. [28] is highly unlikely to be due to analytical differences. It may rather reflect a specific molecular abnormality of THP in our highly selected recurrent calcium stone formers with positive family history.

This study confirms once more that aggregation of COM crystals is modulated by the presence of THP at physiologic concentrations. Furthermore, we again find reduced crystal aggregation inhibition or even aggregation promotion by THPs from recurrent stone formers, at least under conditions of physiologically high ionic strength at solution pH 5.7 [14, 15]. Previous data indicated that THP function, i.e., crystal aggregation inhibition, was significantly related to THP structure, assessed by measurements of intrinsic viscosity [14]. In the present study, we did not find a correlation between THP function and structural data, i.e., elution patterns of THP molecules. Most likely, intrinsic viscosity is a more accurate index of molecular THP conformation with respect to THP interaction with urinary crystals.

At this point, it has to be emphasized that human urine contains many molecules which act as modulators of crystallization [29]. Obviously, one single molecule such as THP cannot be considered fully responsible for all modulatory actions on urinary crystallization and crystal retention. Furthermore, interactions between various crystallization modulators, as demonstrated for instance for citrate and THP [14, 24], ought to be considered; this was beyond the scope of the present study. Moreover, animal models and renal cell culture studies show increased synthesis of THP as well as of other inhibitory macromolecules on exposure to high oxalate and/or calcium oxalate crystals [10, 29]. It therefore seems reasonable to envision that intermittent high peaks of urinary oxalate concentrations (for instance after meals), although not detected by routine 24-h urine analysis, may induce a rise in the synthesis of potentially “harmful” macromolecules such as THP in genetically predisposed individuals.

In conclusion, our study confirms that THP plays a role in calcium oxalate crystal aggregation and in the formation of calcium oxalate stones. We demonstrate for the first time that severely recurrent idiopathic calcium stone formers with a

positive family history excrete significantly higher amounts of structurally different THP molecules with higher SA contents than age-matched healthy controls. These abnormal stone former THPs are less inhibitory or even promotive toward calcium oxalate crystal aggregation, apparently one of the more important prerequisites for urinary stone formation [7–9]. One can only speculate about the possibility that such abnormal urinary macromolecules might also facilitate the deposition of urinary crystal aggregates on preformed Randall’s plaques in the ducts of Bellini [30].

Acknowledgments The study was partly supported by the Swiss National Science Foundation (Grant 32-43448.95) and by PHSN/NIDDK (grant DK 56788-06).

References

1. Kumar S, Muchmore A (1990) Tamm-Horsfall protein—Uromodulin (1950–1990). *Kidney Int* 37:1395–1401
2. Serrafini-Cessi F, Malagolini N, Cavallone D (2003) Tamm-Horsfall glycoprotein: biology and clinical relevance. *Am J Kidney Dis* 42:658–676
3. Pak J, Pu Y, Zjang Z-T, Hasty DL, Wu X-R (2001) Tamm-Horsfall protein binds to type 1 fimbriated *Escherichia coli* and prevents *E. coli* from binding to uroplakin Ia and Ib receptors. *J Biol Chem* 276:9924–9930
4. Bates JM, Raffi HM, Prasad K, Mascarenhas R, Laszik Z, Maeda N, Hultgren SJ, Kumar S (2004) Tamm-Horsfall protein knock-out mice are more prone to urinary tract infection: rapid communication. *Kidney Int* 65:791–797
5. Wimmer T, Cohen G, Saemann MD, Hörl WH (2004) Effects of Tamm-Horsfall protein on polymorphonuclear leukocyte function. *Nephrol Dial Transplant* 19:2192–2197
6. Mo L, Huang H-Y, Zhu X-H, Shapiro E, Hasty DL, Wu X-R (2004) Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. *Kidney Int* 66:1159–1166
7. Hess B, Kok DJ (1996) Nucleation, growth and aggregation of stone-forming crystals. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) *Kidney stones: medical and surgical management*, Chap. 1. Lippincott-Raven Publishers, Philadelphia
8. Fleisch H (1987) Inhibitors and promoters of stone formation. *Kidney Int* 13:361–371
9. Kok DJ, Khan SR (1994) Calcium oxalate nephrolithiasis, a free or fixed particle disease. *Kidney Int* 46:847–854
10. Khan SR (1997) Tubular surface events during nephrolithiasis. *Curr Opin Urol* 7:240–247
11. Scurr DS, Robertson WG (1986) Modifiers of calcium oxalate crystallization found in urine. II. Studies on their mode of action in an artificial urine. *J Urol* 136:128–131
12. Hess B (1994) Tamm-Horsfall glycoprotein and calcium nephrolithiasis. *Miner Electrolyte Metab* 20:393–398
13. Hess B, Nakagawa Y, Coe FL (1989) Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. *Am J Physiol* 257:F99–F106
14. Hess B, Zipperle L, Jaeger Ph (1993) Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. *Am J Physiol* 265:F784–F791
15. Hess B, Nakagawa Y, Parks JH, Coe FL (1991) Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. *Am J Physiol* 260:F569–F578

16. Knörle R, Schmierle P, Koch A, Buchholz N-P, Hering F, Seiler H, Ackermann T, Rutishauser G (1994) Tamm-Horsfall glycoprotein: role in inhibition and promotion of renal calcium oxalate stone formation studied with Fourier-transform infrared spectrometry. *Clin Chem* 40:1739–1743
17. Glauser A, Hochreiter W, Jaeger Ph, Hess B (2000) Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects. *Nephrol Dial Transplant* 14:1580–1587
18. Reinhart HH, Obedeau N, Walz D, Sobel JD (1989). A new ELISA method for the rapid quantification of Tamm-Horsfall protein in urine. *Am J Pathol* 92:199–205
19. Fletcher AP, Neuberger A, Ratcliffe WA (1970) Tamm-Horsfall urinary glycoprotein: the chemical composition. *Biochem J* 120:417–424
20. Aminoff D (1961) Method for the quantitative estimation of *N*-acetylneuraminic acid and their application to hydrolysates of sialomucoids. *Biochem J* 81:384–392
21. Bichler KH, Kirchner Ch, Ideler V (1976) Uromucoid excretion in normal individuals and stone formers. *Br J Urol* 47:733–738
22. Samuell CT (1979) Uromucoid excretion in normal subjects, calcium stone formers and in patients with chronic renal failure. *Urol Res* 7:5–12
23. Thornley C, Dawnay A, Cattell WR (1985) Human Tamm-Horsfall glycoprotein: urinary and plasma levels in normal subjects and patients with renal disease determined by a fully validated radioimmunoassay. *Clin Sci* 68:529–535
24. Erwin DT, Kok DJ, Alam J, et al (1994) Calcium oxalate stone agglomeration reflects stone forming activity: citrate inhibition depends on macromolecules larger than 30 kilodaltons. *Am J Kidney Dis* 24:893–900
25. Romero MC, Nocera S, Nesse AB (1997) Decreased Tamm-Horsfall protein in lithiasic patients. *Clin Biochem* 30:63–67
26. Ganter K, Bongartz D, Hesse A (1999) Tamm-Horsfall protein excretion and its relation to citrate in urine of stone-forming patients. *Urology* 53:492–495
27. Bichler KH, Mittermüller B, Strohmaier WL, Feil G, Eipper E (1999) Excretion of Tamm-Horsfall protein in patients with uric acid stones. *Urol Int* 62:87–92
28. Sumitra K, Pragasam V, Sakthivel R, Kalaiselvi P, Varalakshmi P (2005) Beneficial effects of vitamin E supplementation on the biochemical and kinetic properties of Tamm-Horsfall glycoprotein in hypertensive and hyperoxaluric subjects. *Nephrol Dial Transplant* 20:1407–1415
29. Khan SR (2004) Role of renal epithelial cells in the initiation of calcium oxalate stones. *Nephron Exp Nephrol* 98:e55–e60
30. Coe FL, Evan A, Worcester E (2005) Kidney stone disease. *J Clin Invest* 115:2598–2608